Anti-DNA antibody modified coronary stent for plasmid gene delivery: Results obtained from a porcine coronary stent model

Journal of Gene Medicine

Volumn 13, Issue 1, 2011, Pages 37-45

  Zhang, Lin Hua ^a   Luo, Tong ^b   Zhang, Chao ^a   Luo, Peng ^b   Jin, Xu ^a   Song, Cun Xian ^a   Gao, Run Lin ^b  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Intravascular site specific gene delivery; Nonviral vector; Plasmid DNA; Restenosis; Stent

Indexed keywords

COMPLEMENTARY DNA; DNA ANTIBODY; ENHANCED GREEN FLUORESCENT PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY STENT; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; HISTOPATHOLOGY; MALE; MORPHOLOGY; NEOINTIMA; NONHUMAN; PLASMID; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESTENOSIS; SWINE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, ANTINUCLEAR; CORONARY RESTENOSIS; CORONARY VESSELS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; MALE; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE II; PLASMIDS; STENTS; SWINE; SWINE, MINIATURE; TRANSFECTION;

ORYCTOLAGUS CUNICULUS; SUIDAE; SUS;

EID: 78751698532     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1529     Document Type: Article

References (52)

1. Fishbein I, Chorny M, Levy RJ. Site-specific gene therapy for cardiovascular disease. Curr Opin Drug Discov Devel 2010; 13: 203-213.
2. Luis GM, Alok SP, Massimiliano G, et al. Genetic therapies for cardiovascular diseases. Trends Mol Med 2005; 11: 240-250.
3. Gruchala M, Roy H, Bhardwaj S, et al. Gene therapy for cardiovascular diseases. Curr Pharm Des 2004; 10: 407-423.
4. Ylä-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-222.
5. Gaffney MM, Hynes SO, Barry F, et al. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 2007; 152: 175-188.
6. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther 2010; 17: 439-447.
7. Su CH, Yeh HI, Hou CJY, et al. Nonviral technologies for gene therapy in cardiovascular research. Int J Gerontolog 2008; 2: 35-47.
8. Jo J, Tabata Y. Non-viral gene transfection technologies for genetic engineering of stem cells. Eur J Pharm Biopharm 2008; 68: 90-104.
9. Brewster LP, Brey EM, Greisler HP. Cardiovascular gene delivery: the good road is awaiting. Adv Drug Deliv Rev 2006; 58: 604-629.
10. Kaouass M, Beaulieu R, Balicki D. Histonefection: novel and potent non-viral gene delivery. J Control Release 2006; 113: 245-254.
11. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 24: 1647-1652.
12. Audouy SA, de Leij LF, Hoekstra D, et al. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002; 19: 1599-1605.
13. Pedroso de Lima MC, Neves S, Filipe A, et al. Cationic liposomes for gene delivery: from biophysics to biological applications. Curr Med Chem 2003; 10: 1221-1231.
14. Kuramoto T, Nishikawa M, Thanaketpaisarn O, et al. Use of lipoplex-induced nuclear factor-kappaB activation to enhance transgene expression by lipoplex in mouse lung. J Gene Med 2006; 8: 53-62.
15. Yang Z, Sahay G, Sriadibhatla S, et al. Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug Chem 2008; 19: 1987-94.
16. Fischer D, Bieber T, Li Y, et al. A novel nonviral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999; 16: 1273-1279.
17. Brunner S, Furtbauer E, Sauer T, et al. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol Ther 2002; 5: 80-86.
18. Burton DY, Song C, Fishbein I, et al. The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studies. Hum Gene Ther 2003; 14: 907-922.
19. Kapadia MR, Chow LW, Tsihlis ND, et al. Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. J Vasc Surg 2008; 47: 173-182.
20. Kook H, Ahn KY, Lee SE, et al. Nitric oxide-dependent cytoskeletal changes and inhibition of endothelial cell migration contribute to the suppression of angiogenesis by RAD50 gene transfer. FEBS Lett 2003; 553: 56-62.
21. O'Connor DM, O'Brien T. Nitric oxide synthase gene therapy: progress and prospects. Expert Opin Biol Ther 2009; 9: 867-878.
22. Kibbe MR, Nie S, Yoneyama T, et al. Optimization of ex-vivo inducible nitric oxide synthase gene transfer to vein grafts. Surgery 1999; 126: 323-329.
23. Barbato JE, Tzeng E. iNOS gene transfer for graft disease. Trends in Cardiovasc Med 2004; 14: 267-272.
24. Tzeng E, Kim YM, Pitt BR, et al. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery 1997; 122: 255-263.
25. Shears LL II, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirusmediated inducible nitric oxide synthase gene transfer to rats and pigs invivo. J Am Coll Surg 1998; 187: 295-306.
26. Klugherz BD, Song C, DeFelice S, et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002; 13: 443-454.
27. Mei L, Jin X, Song C, et al. Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy. J Gene Med 2008; 10: 421-429.
28. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipidmediatedDNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
29. Yanase K, Smith RM, Puccetti A, et al. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997; 100: 25-31.
30. Zack DJ, Stempniak M, Wong ML, et al. Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J Immunol 1996; 157: 2082-2088.
31. Avrameas A, Gasmi L, Buttin G. DNA and heparin alter the internalization process of anti-DNA monoclonal antibodies according to patterns typical of both the charged molecule and the antibody. J Autoimmun 2001; 16: 383-391.
32. McCormick C, Wadsworth RM, Jones RL. Prostacyclin analogues: the next drug-eluting stent? Biochem Soc Trans 2007; 35: 910-911.
33. Chen SY, Wang F, Yan XY, et al. Autologous transplantation of EPCs encoding FGF1 gene promotes neovascularization in a porcine model of chronic myocardial ischemia. Int J Cardiol 2009; 135: 223-232.
34. 2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation 2008; 118: 614-624.
35. Raake PW, Hinkel R, Müller S, et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008; 15: 12-17.
36. Buchwald AB, Kunze C, Waltenberger J, et al. Transfection of the DNA for the receptor KDR/flk-1 attenuates neointimal proliferation and luminal narrowing in a coronary stent angioplasty model. J Surg Res 2006; 136: 120-124.
37. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-193.
38. Nelken N, Schneider PA. Advances in stent technology and drug-eluting stents. Surg Clin North Am 2004; 84: 1203-1236.
39. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193.
40. Grube E, Sonoda S, Ikeno F, et al. Six- and 12-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109: 2168-2171.
41. Mani G, Feldman MD, Patel D, et al. Coronary stents: a materials perspective. Biomaterials 2007; 28: 1689-1710.
42. Tavakalyan NB, Karapetyan AG, Pogosyan AS, et al. Influence of unsaturated carbonic acids on hemocompatibility and cytotoxicity of poly vinylacetate based co-polymers. J Mater Sci Mater Med 2010; 21: 1693-1702.
43. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation 2002; 106: 2859-2866.
44. Lyell A, Bain WH, Thomson RM. Repeated failure of nickelcontaining prosthetic heart valves in a patient allergic to nickel. Lancet 1978; 2: 657-59.
45. Kanerva L, Sipilänen MT, Estlander T, et al. Nickel release from metals, and a case of allergic contact dermatitis from stainless steel. Contact Dermatitis 1994; 31: 299-303.
46. San Martin M, Barranco Sanz P, Lopez Serrano MC, et al. Allergy to dental prosthesis. Allergy 1997; 52: 690-691.
47. Köster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356: 1895-1897.
48. Indolfi L, Causa F, Netti PA. Coating process and early stage adhesion evaluation of poly(2-hydroxy-ethyl-methacrylate) hydrogel coating of 316L steel surface for stent applications. J Mater Sci Mater Med 2009; 20: 1541-1551.
49. Jang JH, Houchin TL, Shea LD. Gene delivery from polymer scaffolds for tissue engineering. Expert Rev Med Devices 2004; 1: 127-138.
50. Petite H, Frei V, Huc A, et al. Use of diphenylphosphorylazide for cross-linking collagen-based biomaterials. J Biomed Mater Res 1994; 28: 159-165.
51. Yannas IV, Burke JF, Huang C, et al. Correlation of in vivo collagen degradation rate with in vitro measurements. J Biomed Mater Res 1975; 9: 623-628.
52. Weadock KS, Miller EJ, Keuffel EL, et al. Effect of physical crosslinking methods on collagen-fiber durability in proteolytic solutions. J Biomed Mater Res 1996; 32: 221-226.